Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone and Semaglutide in Non-diabetic Adults With Obesity and Albuminuric CKD
NCT07849348Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Sep 2026
- Primary completion
- Feb 2027
01
Overview
Randomised, double-blind trial in chronic kidney disease (CKD) and albuminuria comparing Finerenone + Semaglutide with Placebo + Semaglutide (2 arms). Primary endpoint: Change From Baseline in Urinary Albumin-to-Creatinine Ratio at 24 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
finerenone
03
Conditions
chronic kidney disease (CKD)albuminuria
Beyond the preview
Go deeper on NCT07849348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07849348.